MiNK Therapeutics
INKT
15 hedge funds and large institutions have $1.65M invested in MiNK Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.
64% more capital invested
Capital invested by funds: $1M → $1.65M (+$646K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
36% more funds holding
Funds holding: 11 → 15 (+4)
0.05% more ownership
Funds ownership: 0.14% → 0.19% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$25.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.26K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.98K |
| 4 |
BlackRock
New York
|
+$1.15K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$23 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$68.1K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$563 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
1
Artal Group
Luxembourg
| $756K | – | – | – |
|
|
LF
2
Longbow Finance
Lutry,
Switzerland
| $435K | +$391K | +16,667 | New |
|
|
JMPWA
3
JP Morgan Private Wealth Advisors
San Francisco,
California
| $137K | -$68.1K | -2,900 | -36% |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $128K | – | – | – |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $65K | +$4.98K | +212 | +9% |
|
6
State Street
Boston,
Massachusetts
| $28.7K | – | – | – |
|
|
7
Millennium Management
New York
| $28K | +$25.5K | +1,088 | New |
|
|
8
BlackRock
New York
| $27.4K | +$1.15K | +49 | +5% |
|
9
HighTower Advisors
Chicago,
Illinois
| $27K | – | – | – |
|
|
FWA
10
Freedom Wealth Alliance
Brookfield,
Wisconsin
| $8.66K | +$7.79K | +332 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| $6.54K | +$5.26K | +224 | +862% |
|
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$563 | -24 | -51% |
|
13
Morgan Stanley
New York
| $107 | – | – | – |
|
14
Wells Fargo
San Francisco,
California
| $84 | – | – | – |
|
|
15
Bank of America
Charlotte,
North Carolina
| $26 | +$23 | +1 | New |
|
INKT Hedge Fund Activity: Q4 2022 in Review
15 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q4 2022, worth a combined $1.65M — up 64% from $1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new INKT positions and 0 closed out — a net gain of 4 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $25.5K. The largest seller was JP Morgan Private Wealth Advisors, cutting an estimated $68.1K.
- 15 institutional investors held MiNK Therapeutics (INKT) as of Q4 2022, up from 11 in Q3 2022.
- Funds reported $1.65M of MiNK Therapeutics stock for Q4 2022, up 64% quarter-over-quarter.
- 4 funds opened new MiNK Therapeutics positions in Q4 2022 and 0 closed out, a net change of +4 holders.
- The largest MiNK Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $25.5K added.
- The largest MiNK Therapeutics seller in Q4 2022 was JP Morgan Private Wealth Advisors, an estimated $68.1K sold.
Based on aggregated 13F filings for Q4 2022.